Erbitux TAILOR-Made For China First-Line mCRC Market, But Brand Recognition Merck’s Real Goal?
This article was originally published in PharmAsia News
Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux have received a boost with the Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.
You may also be interested in...
German group Merck has inaugurated a major new pharmaceutical plant and announced a further investment in China, where it sees opportunities in essential drugs amid rising demand as the country broadens its basic healthcare coverage and its population ages.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.